CoChat

Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders

ALBANESE, MARK J., SUH, JESSE J. · 2006 · Journal of Psychiatric Practice

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

BACKGROUND: : A high percentage of individuals with cocaine dependence have a comorbid psychiatric illness, which complicates treatment of the substance abuse. This report will describe clinical experience using risperidone in cocaine-dependent patients with psychiatric disorders. METHOD: : Sixteen male patients with cocaine dependence and comorbid psychiatric disorder (DSM-III-R) diagnoses, who were admitted to a voluntary, post-detoxification, intermediate-care inpatient substance abuse program, were started on risperidone (mean starting dose 2.3 mg/day) in an open-label, naturalistic trial. Patients were assessed weekly using the Clinical Global Impressions scale to assess overall functioning, a Likert scale for craving, the Abnormal Involuntary Movement Scale, interviews with substance abuse counselors and patients, and laboratory tests. All patients had at least one other substance use diagnosis besides cocaine dependence, and 13 patients were taking another psychiatric medication. RESULTS: : Of the 16 patients, 13 (81%) were rated improved or much improved on the CGI scale, and all patients reported mild or no craving at the last assessment (after a mean of 32.6 days of risperidone treatment). No patient developed extrapyramidal symptoms or hypomania. Compared to a 32% historical completion rate for patients receiving treatment as usual, fourteen (88%) of these patients completed the program, and 9 moved on to the next level of care. CONCLUSION: : The results of this naturalistic trial suggest that risperidone is safe and well tolerated in patients with cocaine dependence and comorbid psychiatric illness. In the short term, risperidone may also be effective in reducing cocaine craving and use and may increase the likelihood of completing substance abuse treatment.

Overview

Integrity signals

Registry

Crossref · 10.1097/00131746-200609000-00005

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Albanese, 1994, Am J Psychiatry, 151, 780
  2. Conley, 1997, Schizophr Res, 24, 190

Cited by

See all 20

Metadata

Authors
ALBANESE, M. J., & SUH, J. J.
Affiliations
Cambridge Health Alliance (US)
Venue
Journal of Psychiatric Practice
Published
2006-09
Volume
12
Issue
5
Pages
306-311
ISSN
  • 1527-4160 (ISSN-L)
  • 1538-1145
OpenAlex
W2079646955
Cited by
20
References
26
Citations by year
2025: 1 · 2021: 1 · 2018: 2 · 2017: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
FWCI
0.72
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Psychiatric Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
risperidone, cocaine dependence, psychiatric comorbidity, cocaine craving, addiction treatment, treatment completion, extrapyramidal symptoms, hypomania
MeSH terms
Adolescent, Adult, Mental Disorders, Counseling, Health Status, Humans, Disruptive, Impulse Control, and Conduct Disorders, Intermediate Care Facilities, Male, Inactivation, Metabolic, Middle Aged, Surveys and Questionnaires, Severity of Illness Index, Time Factors, Antipsychotic Agents, Comorbidity, Diagnosis, Dual (Psychiatry), Risperidone, Cocaine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders. https://app.cochat.ai/papers/10.1097/00131746-200609000-00005
The paper
ALBANESE, M. J., & SUH, J. J. (2006). Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders. Journal of Psychiatric Practice. https://doi.org/10.1097/00131746-200609000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.